Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Teva
Chinese Patent Office
Cipla
Deloitte
Dow
Cerilliant
Julphar

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR APIXABAN

« Back to Dashboard

Clinical Trials for Apixaban

Trial ID Title Status Sponsor Phase Summary
NCT00097357 BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery Completed Bristol-Myers Squibb Phase 2/Phase 3 The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
NCT00252005 Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study Completed Bristol-Myers Squibb Phase 2 The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.
NCT00313300 Safety Study of Apixaban in Recent Acute Coronary Syndrome Completed Bristol-Myers Squibb Phase 2 The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
NCT00320255 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer Completed Ontario Clinical Oncology Group (OCOG) Phase 2 The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.
NCT00320255 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer Completed Bristol-Myers Squibb Phase 2 The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.
NCT00371683 Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery Completed Bristol-Myers Squibb Phase 3 The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Apixaban

Condition Name

Condition Name for Apixaban
Intervention Trials
Atrial Fibrillation 31
Venous Thromboembolism 20
Pulmonary Embolism 12
Deep Vein Thrombosis 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Apixaban
Intervention Trials
Atrial Fibrillation 43
Thrombosis 29
Thromboembolism 26
Venous Thromboembolism 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Apixaban

Trials by Country

Trials by Country for Apixaban
Location Trials
United States 528
United Kingdom 109
Canada 99
Mexico 93
Brazil 76
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Apixaban
Location Trials
California 24
Texas 23
Pennsylvania 22
Florida 21
North Carolina 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Apixaban

Clinical Trial Phase

Clinical Trial Phase for Apixaban
Clinical Trial Phase Trials
Phase 4 28
Phase 3 30
Phase 2/Phase 3 7
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Apixaban
Clinical Trial Phase Trials
Recruiting 51
Completed 35
Not yet recruiting 27
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Apixaban

Sponsor Name

Sponsor Name for Apixaban
Sponsor Trials
Bristol-Myers Squibb 70
Pfizer 28
Assistance Publique - Hôpitaux de Paris 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Apixaban
Sponsor Trials
Other 120
Industry 110
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
Fuji
Dow
Farmers Insurance
Express Scripts
Cipla
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.